| Dry Eye Syndromes
Miebo vs Lacrisert
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Miebo vs Lacrisert with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLacrisert has a higher rate of injection site reactions vs Miebo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lacrisert but not Miebo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Miebo
Lacrisert
At A Glance
Topical (ophthalmic)
4 times daily
Semifluorinated alkane
Ophthalmic insert
Once daily
Ocular lubricant
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Exposure keratoconjunctivitis
- Corneal hypoesthesia
- Recurrent erosion of cornea
Dosing
Dry Eye Syndromes Instill one drop four times daily into each affected eye; remove contact lenses prior to and for at least 30 minutes after administration.
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Exposure keratoconjunctivitis, Corneal hypoesthesia, Recurrent erosion of cornea One ophthalmic insert in each eye once daily; some patients may require twice daily use for optimal results; insert into the inferior cul-de-sac of the eye beneath the base of the tarsus.
Contraindications
- History of hypersensitivity reaction to perfluorohexyloctane
- Hypersensitivity to hydroxypropyl cellulose
Adverse Reactions
Most common (<4%) blurred vision, conjunctival redness
Premarketing studies hypersensitivity
Most common Transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, hyperemia
Pharmacology
Perfluorohexyloctane, a semifluorinated alkane, forms a monolayer at the air-liquid interface of the tear film that may reduce evaporation; the exact mechanism of action in dry eye disease is not known.
Ocular lubricant; stabilizes and thickens the precorneal tear film and prolongs tear film breakup time to reduce signs and symptoms of dry eye syndromes, including lubrication and protection of the eye.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Miebo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (11/12)
Lacrisert
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Miebo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Lacrisert
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Miebo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Lacrisert
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Thyroid Eye Disease (TED)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Lacrisert.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LacrisertView full Lacrisert profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.